Graeme J. Moyle

Corporate Officer/Principal bei Chelsea & Westminster Hospital

60 Jahre

Health Technology

Consumer Services

Profil

Graeme J.
Moyle is currently the Director-HIV Research Strategy at Chelsea & Westminster Hospital since 1994.
He previously worked as an Independent Director at Tobira Therapeutics, Inc. Dr. Moyle holds a doctorate degree from the University of Adelaide.

Aktive Positionen von Graeme J. Moyle

Unternehmen	Position	Beginn
Chelsea & Westminster Hospital	Corporate Officer/Principal	01.01.1994

Alle aktiven Positionen von Graeme J. Moyle

Ehemalige bekannte Positionen von Graeme J. Moyle

Unternehmen	Position	Ende
Tobira Therapeutics, Inc. /Old/ Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA.	Direktor/Vorstandsmitglied	-

Sehen Sie sich die Erfahrung von Graeme J. Moyle im Detail an

Ausbildung von Graeme J. Moyle

University of Adelaide

Doctorate Degree

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Graeme J. Moyle im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	2
Tobira Therapeutics, Inc. /Old/ Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA.	Health Technology
Chelsea & Westminster Hospital